Susan Glasser

Adverse Event Detection in Drug Development: Recommendations and Obligations Beyond Phase 3

Jesse A. Berlin, Susan Glasser, Susan S. Ellenberg · American Journal of Public Health · 2008 · 204 citations · Full text

Pharmacy, Pharmacology, Clinical Pharmacology +14

Recommendations to improve adverse event reporting in clinical trial publications: a joint pharmaceutical industry/journal editor perspective

Neil Lineberry, Jesse A. Berlin, Bernadette Mansi et al. · BMJ · 2016 · 118 citations · Full text

Health Professions, Pharmaceutical Policy, Evidence-based Practice +16

Ten Recommendations for Closing the Credibility Gap in Reporting Industry-Sponsored Clinical Research: A Joint Journal and Pharmaceutical Industry Perspective

Bernadette Mansi, Juli Clark, Frank David et al. · Mayo Clinic Proceedings · 2012 · 62 citations · Full text

Pharmacy, Pharmaceutical Policy, Pharmacovigilance +14

Use of Adjectives in Abstracts when Reporting Results of Randomized, Controlled Trials from Industry and Academia

M. Soledad Cepeda, Jesse A. Berlin, Susan Glasser et al. · Drugs in R&D · 2015 · 11 citations · Full text

Pharmacy, Biostatistics, Comparative Effectiveness Research +11